Optimization of guideline-directed medical treatment for heart failure patients with reduced ejection fraction

키워드

참고문헌 (86)

1. Park Jin Joo, "Heart Failure Statistics in Korea, 2020: A Report from the Korean Society of Heart Failure", International Journal of Heart Failure, 3(4), pp.224~ (2021), 대한심부전학회[DOI]
2. 최홍미, "Update on heart failure management and future directions", The Korean Journal of Internal Medicine, 34(1), pp.11~43 (2019), 대한내과학회[DOI]
3. Jin Joo Park, "Current status of heart failure: global and Korea", The Korean Journal of Internal Medicine, 35(3), pp.487~497 (2020), 대한내과학회[DOI]
4. Jung Mi-Hyang, "A Practical Way to Reduce Healthcare Costs in Patients With Heart Failure: Outpatient IV Diuretics Therapy", International Journal of Heart Failure, 4(1), pp.24~ (2022), 대한심부전학회[DOI]
5. Heidenreich PA, "2022 AHA", ACC, American Heart Association Joint Committee on Clinical Practice Guidelines, pp.J Am Coll Cardiol, 2022[DOI]
6. McDonagh TA, "2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure", Eur Heart J, 42, pp.3599~3726 (2021)
7. Jae Yeong Cho, "Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Definition and Diagnosis", Korean Circulation Journal, 53(4), pp.195~216 (2023), 대한심장학회[DOI]
8. Solomon SD, "Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction", Eur Heart J, 37, pp.455~462 (2016)
9. Solomon SD, "Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction", N Engl J Med, 381, pp.1609~1620 (2019)
10. Lund LH, "Heart failure with mid-range ejection fraction in CHARM : characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum", Eur J Heart Fail, 20, pp.1230~1239 (2018)
11. Lam CSP, "DELIVERing therapeutic efficacy across the ejection fraction spectrum of heart failure", Circulation, 146, pp.1193~1195 (2022)
12. Bhosale KH, "Rate of rehospitalization in 60 days of discharge and it’s determinants in patients with heart failure with reduced ejection fraction in a tertiary care centre in India", Int J Heart Fail, 2, pp.131~144 (2020)
13. Shah KS, "Heart failure with preserved, borderline, and reduced ejection fraction : 5-year outcomes", J Am Coll Cardiol, 70, pp.2476~2486 (2017)
14. McMurray JJ, "Angiotensin-neprilysin inhibition versus enalapril in heart failure", N Engl J Med, 371, pp.993~1004 (2014)
15. Lee HY, "Paradigm shifts of heart failure therapy : do we need another paradigm?", Int J Heart Fail, 2, pp.145~156 (2020)
16. Hong-Mi Choi, "Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence", The Korean Journal of Internal Medicine, 35(3), pp.498~513 (2020), 대한내과학회[DOI]
17. Kerr Brian, "Angiotensin Receptor Neprilysin Inhibitors in HFrEF: Is This the First Disease Modifying Therapy Drug Class Leading to a Substantial Reduction in Diuretic Need?", International Journal of Heart Failure, 3(2), pp.106~ (2021), 대한심부전학회[DOI]
18. Talha Khawaja M., "SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence", International Journal of Heart Failure, 5(2), pp.82~90 (2023), 대한심부전학회[DOI]
19. Youn Jong-Chan, "Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment", International Journal of Heart Failure, 5(2), pp.66~81 (2023), 대한심부전학회[DOI]
20. Packer M, "Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group", Circulation, 100, pp.2312~2318 (1999)
21. Konstam MA, "HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial", Lancet, 374, pp.1840~1848 (2009)
22. Bristow MR, "Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators", Circulation, 94, pp.2807~2816 (1996)
23. ), "Am J Cardiol", 1996, 902~907
24. Mebazaa A, "Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure(STRONG-HF) : a multinational, open-label, randomised, trial", Lancet, 400, pp.1938~1952 (2022)
25. Willenheimer R, "Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS)III", Circulation, 112, pp.2426~2435 (2005)
26. Se-Eun Kim, "Treatment Strategies of Improving Quality of Care in Patients With Heart Failure", Korean Circulation Journal, 53(5), pp.294~312 (2023), 대한심장학회[DOI]
27. Greene SJ, "Medical therapy for heart failure with reduced ejection fraction : the CHAMP-HF registry", J Am Coll Cardiol, 72, pp.351~366 (2018)
28. Park Jin Joo, "Real-World Usage of Sacubitril", Valsartan in Korea: A Multi-Center, Retrospective Study, 2022, pp.4(4), 193~[DOI]
29. Peri-Okonny PA, "Target doses of heart failure medical therapy and blood pressure : insights from the CHAMP-HF registry", JACC Heart Fail, 7, pp.350~358 (2019)
30. "Angiotensin-neprilysin inhibition in acute decompensated heart failure", N Engl J Med, 380, pp.1090~ (2019)
31. Sanam K, "Renin-angiotensin system inhibition and lower 30-day all-cause readmission in medicare beneficiaries with heart failure", Am J Med, 129, pp.1067~1073 (2016)
32. Tomasoni D, "Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction", Eur J Heart Fail, 24, pp.431~441 (2022)
33. Helsi Rismiati, "The role of discharge checklist in guideline-directed medical therapy for heart failure patients", The Korean Journal of Internal Medicine, 38(2), pp.195~206 (2023), 대한내과학회[DOI]
34. Kim JJ, "Eligibility and usage of sacubitril", valsartan in Korea, 2019, pp.1, 69~71
35. Oh J, "Real-world eligibility for sacubitril", valsartan in heart failure with reduced ejection fraction patients in Korea : data from the Korean Acute Heart Failure(KorAHF)registry, 2019, pp.1, 57~68
36. Marti CN, "Medication dosing for heart failure with reduced ejection fraction-opportunities and challenges", Eur J Heart Fail, 21, pp.286~296 (2019)
37. Rosano GMC, "Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology", Eur J Heart Fail, 23, pp.872~881 (2021)
38. Böhm M, "Optimization of heart failure treatment by heart rate reduction", Int J Heart Fail, 2, pp.1~11 (2019)
39. Hesse K, "Target heart rate in heart failure with reduced ejection fraction and atrial fibrillation : Goldilocks zone", Am Heart J Plus Cardiol Res Pract, 23, pp.100218~ (2022)
40. Hyun-Jin Kim, "The effect of beta-blockers in acute heart failure according to heart rate", The Korean Journal of Internal Medicine, 36(4), pp.898~905 (2021), 대한내과학회[DOI]
41. Heusch G, "Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia : benefit from selective bradycardic agents", Br J Pharmacol, 153, pp.1589~1601 (2008)
42. Volterrani M, "Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure(the CARVIVA HF trial)", Int J Cardiol, 151, pp.218~224 (2011)
43. Damman K, "The kidney in heart failure : an update", Eur Heart J, 36, pp.1437~1444 (2015)
44. Youn Jong-Chan, "A Noteworthy Way to Predict Acute Decompensated Heart Failure in Patients With End-Stage Renal Disease", International Journal of Heart Failure, 4(3), pp.142~ (2022), 대한심부전학회[DOI]
45. Kim Bong-Joon, "Increased Right Ventricular Pressure as a Predictor of Acute Decompensated Heart Failure in End-Stage Renal Disease Patients on Maintenance Hemodialysis", International Journal of Heart Failure, 4(3), pp.154~ (2022), 대한심부전학회[DOI]
46. Damman K, "Progression of renal impairment and chronic kidney disease in chronic heart failure : an analysis from GISSI-HF", J Card Fail, 23, pp.2~9 (2017)
47. Clark H, "Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction", Eur J Heart Fail, 16, pp.41~48 (2014)
48. Jang Se Yong, "Prognostic and Therapeutic Implications of Renal Insufficiency in Heart Failure", International Journal of Heart Failure, 4(2), pp.75~ (2022), 대한심부전학회[DOI]
49. Mullens W, "Renal effects of guideline-directed medical therapies in heart failure : a consensus document from the Heart Failure Association of the European Society of Cardiology", Eur J Heart Fail, 24, pp.603~619 (2022)
50. Kato ET, "Sodium-glucose co-transporters-2 inhibitors and heart failure : state of the art review and future potentials", Int J Heart Fail, 2, pp.12~22 (2020)
51. Verma S, "Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure", Eur Heart J, 43, pp.2994~2996 (2022)
52. Mc Causland FR, "Angiotensinneprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction", Circulation, 142, pp.1236~1245 (2020)
53. Lee S, "Sacubitril", valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease, 2020, pp.7, 1125~1129
54. Badve SV, "Effects of beta-adrenergic antagonists in patients with chronic kidney disease : a systematic review and meta-analysis", J Am Coll Cardiol, 58, pp.1152~1161 (2011)
55. Cice G, "Carvedilol increases twoyear survivalin dialysis patients with dilated cardiomyopathy : a prospective, placebo-controlled trial", J Am Coll Cardiol, 41, pp.1438~1444 (2003)
56. Butler J, "Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction : the DIAMOND trial", Eur Heart J, 43, pp.4362~4373 (2022)
57. Kim D, "Untangling amyloidosis : recent advances in cardiac amyloidosis", Int J Heart Fail, 2, pp.231~239 (2020)
58. Ammirati E, "Pharmacological treatment of hypertrophic cardiomyopathy : current practice and novel perspectives", Eur J Heart Fail, 18, pp.1106~1118 (2016)
59. 박예민, "Updated risk assessments for sudden cardiac death in hypertrophic cardiomyopathy patients with implantable cardioverter-defibrillator", The Korean Journal of Internal Medicine, 38(1), pp.7~15 (2023), 대한내과학회[DOI]
60. Hyun-Jung Lee, "Major Clinical Issues in Hypertrophic Cardiomyopathy", Korean Circulation Journal, 52(8), pp.563~575 (2022), 대한심장학회[DOI]
61. Voors AA, "The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure : a multinational randomized trial", Nat Med, 28, pp.568~574 (2022)
62. Takagi K, "Management of acute heart failure during an early phase", Int J Heart Fail, 2, pp.91~110 (2020)
63. Ponikowski P, "Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial", Lancet, 396, pp.1895~1904 (2020)
64. 김민철, "Pre-discharge anemia as a predictor of adverse clinical outcomes in patients with acute decompensated heart failure", The Korean Journal of Internal Medicine, 34(3), pp.549~558 (2019), 대한내과학회[DOI]
65. Lewis GD, "Oral iron therapy for heart failure with reduced ejection fraction : design and rationale for oral iron repletion effects on oxygen uptake in heart failure", Circ Heart Fail, 9, pp.e000345~ (2016)
66. Ferreira JP, "Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction : findings from EMPEROR-Reduced", Eur J Heart Fail, 24, pp.708~715 (2022)
67. 이규선, "Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement", Diabetes and Metabolism Journal, 47(1), pp.10~26 (2023), 대한당뇨병학회[DOI]
68. Lind M, "Glycaemic control and incidence of heart failure in 20, 985 patients with type 1 diabetes : an observational study", Lancet, 378, pp.140~146 (2011)
69. Giugliano D, "GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes : an updated meta-analysis of eight CVOTs", Cardiovasc Diabetol, 20, pp.189~ (2021)
70. Margulies KB, "NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial", JAMA, 316, pp.500~508 (2016)
71. Jorsal A, "Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes(LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial", Eur J Heart Fail, 19, pp.69~77 (2017)
72. Seferović PM, "European Society of Cardiology", Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure, 2020, pp.22, 196~213
73. Gangu Karthik, "In-Hospital Mortality Rate and Predictors of 30-Day Readmission in Patients With Heart Failure Exacerbation and Atrial Fibrillation: A Cross-Sectional Study", International Journal of Heart Failure, 4(3), pp.145~ (2022), 대한심부전학회[DOI]
74. Kim Yun Gi, "Interaction Between Heart Failure and Atrial Fibrillation", International Journal of Heart Failure, 4(3), pp.139~ (2022), 대한심부전학회[DOI]
75. Kim Hee-Dong, "Left Atrial Dysfunction, Fibrosis and the Risk of Thromboembolism in Patients With Paroxysmal and Persistent Atrial Fibrillation", International Journal of Heart Failure, 4(1), pp.42~ (2022), 대한심부전학회[DOI]
76. Daehoon Kim, "Optimal Rhythm Control Strategy in Patients With Atrial Fibrillation", Korean Circulation Journal, 52(7), pp.496~512 (2022), 대한심장학회[DOI]
77. Banerjee A, "Ejection fraction and outcomes in patients with atrial fibrillation and heart failure : the Loire Valley Atrial Fibrillation Project", Eur J Heart Fail, 14, pp.295~301 (2012)
78. Chung Hyemoon, "Left Atrial Remodeling and Thromboembolic Risk in Patients With Atrial Fibrillation", International Journal of Heart Failure, 4(1), pp.26~ (2022), 대한심부전학회[DOI]
79. Carlisle MA, "Heart failure and atrial fibrillation, like fire and fury", JACC Heart Fail, 7, pp.447~456 (2019)
80. Colin-Ramirez E, "Sodium restriction in patients with heart failure : a systematic review and meta-analysis of randomized clinical trials", Circ Heart Fail, 16, pp.e009879~ (2023)
81. Camafort Miguel, "Lifestyle Modification in Heart Failure Management: Are We Using Evidence-Based Recommendations in Real World Practice?", International Journal of Heart Failure, 5(1), pp.21~33 (2023), 대한심부전학회[DOI]
82. Alejandra García-García, "Is there sufficient evidence to justify changes in dietary habits in heart failure patients? A systematic review", The Korean Journal of Internal Medicine, 37(1), pp.37~47 (2022), 대한내과학회[DOI]
83. Reilly CM, "Isolating the benefits of fluid restriction in patients with heart failure : a pilot study", Eur J Cardiovasc Nurs, 14, pp.495~505 (2015)
84. Herrmann JJ, "Fluid REStriction in heart failure vs liberal fluid UPtake : rationale and design of the randomized FRESH-UP study", J Card Fail, 28, pp.1522~1530 (2022)
85. Chun KH, "Cardiac rehabilitation in heart failure", Int J Heart Fail, 3, pp.1~14 (2020)
86. Kensuke Ueno, "Effectiveness and Approach of Rehabilitation in Patients With Acute Heart Failure: A Review", Korean Circulation Journal, 52(8), pp.576~592 (2022), 대한심장학회[DOI]

관련 논문AI추천